Champions Oncology Inc (CSBR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Champions Oncology Inc (CSBR) has a cash flow conversion efficiency ratio of -0.306x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($4.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Champions Oncology Inc's balance sheet to measure how much of total assets are equity-financed.
Champions Oncology Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Champions Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CSBR operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Champions Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Champions Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TOPTEC Co. Ltd
KQ:108230
|
-0.065x |
|
Tailim Packaging Co Ltd
KO:011280
|
0.007x |
|
Shanghai Haohai Biological Technology Co. Ltd
F:5HB
|
0.024x |
|
Turker Proje Gayrimenkul Ve Yatirim Gelistirme AS
IS:TURGG
|
-0.003x |
|
Libertas 7 SA
MC:LIB
|
-0.008x |
|
Foshan Electrical and Lighting Co Ltd
SHE:200541
|
0.012x |
|
Canyon Resources Ltd
AU:CAY
|
-0.257x |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Champions Oncology Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Champions Oncology Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see CSBR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $3.77 Million | $7.39 Million | 1.958x | -39.28% |
| 2024-04-30 | $-1.90 Million | $-6.14 Million | 3.225x | +278.02% |
| 2023-04-30 | $4.64 Million | $3.96 Million | 0.853x | +19.44% |
| 2022-04-30 | $9.10 Million | $6.50 Million | 0.714x | +415.62% |
| 2021-04-30 | $7.43 Million | $-1.68 Million | -0.226x | -139.72% |
| 2020-04-30 | $5.10 Million | $2.90 Million | 0.570x | -31.52% |
| 2019-04-30 | $2.24 Million | $1.86 Million | 0.832x | -98.30% |
| 2018-04-30 | $-25.00K | $-1.23 Million | 49.040x | +790.70% |
| 2017-04-30 | $400.00K | $-2.84 Million | -7.100x | +73.81% |
| 2016-04-30 | $238.00K | $-6.45 Million | -27.109x | -2168.67% |
| 2015-04-30 | $8.06 Million | $-9.63 Million | -1.195x | -11.28% |
| 2014-04-30 | $3.20 Million | $-3.43 Million | -1.074x | -91.58% |
| 2013-04-30 | $7.60 Million | $-4.26 Million | -0.560x | -156.60% |
| 2012-04-30 | $-5.28 Million | $-5.23 Million | 0.990x | +134.85% |
| 2011-04-30 | $19.00K | $-54.00K | -2.842x | -113.43% |
| 2010-04-30 | $1.58 Million | $-2.10 Million | -1.332x | -187.32% |
| 2009-04-30 | $1.92 Million | $-888.00K | -0.463x | -312.75% |
| 2008-04-30 | $3.64 Million | $792.40K | 0.218x | -27.53% |
| 2007-04-30 | $-261.06K | $-78.47K | 0.301x | +114.48% |
| 2006-04-30 | $-670.51K | $-93.97K | 0.140x | +44.39% |
| 2005-04-30 | $-366.80K | $-35.60K | 0.097x | -87.51% |
| 2004-04-30 | $-92.70K | $-72.05K | 0.777x | -34.29% |
| 2003-04-30 | $-209.75K | $-248.12K | 1.183x | -81.89% |
| 2002-04-30 | $-5.00K | $-32.68K | 6.530x | +581.82% |
| 2001-04-30 | $151.06K | $144.68K | 0.958x | +4754.15% |
| 2000-04-30 | $891.69K | $-18.35K | -0.021x | -116.65% |
| 1999-04-30 | $890.00K | $110.00K | 0.124x | -72.34% |
| 1998-04-30 | $940.00K | $420.00K | 0.447x | +164.02% |
| 1997-04-30 | $650.00K | $110.00K | 0.169x | +342.56% |
| 1996-04-30 | $430.00K | $-30.00K | -0.070x | -- |
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more